問卷

TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

更新時間:2023-09-19

王振宇
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

26Cases

2026-08-15 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
  • Condition/Disease

    Renal Insufficiency, Chronic

  • Test Drug

    膠囊劑 錠劑

Participate Sites
16Sites

Not yet recruiting16Sites

2024-01-22 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2013-07-01 - 2015-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-08-01 - 2025-12-23

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

2024-01-01 - 2027-02-28

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2024-08-01 - 2026-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2014-05-01 - 2015-12-31

Phase III

A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared with Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects with Chronic Obstructive Pulmonary Disease (COPD)
  • Condition/Disease

    Chronic Obstructive Pulmonary Disease (COPD)

  • Test Drug

    Fluticasone Furoate/Vilanterol

Participate Sites
5Sites

Terminated5Sites

1 2 3